It is devastating to hear Kadcyla – a crucial life-extending treatment for women with incurable secondary breast cancer – faces being withdrawn from the NHS, following the failure of the National Institute for Health and Care Excellence and Roche, the drug’s manufacturer, to reach an agreement.
Kadcyla can offer patients precious extra months – even years – of good quality time with their loved ones, with fewer side effects than other treatments.
It is available in many other countries – including France, Germany and Australia – and unless NICE’s draft decision is overturned next month, this fantastic medical advance will bypass patients in England forever.
That’s why I’ve backed Breast Cancer Now’s campaign to #KeepKadcyla, which calls on NICE and Roche to urgently reach a deal to ensure patients in England are not denied this effective treatment. There is little time left for this decision to be reversed and I urge NICE and Roche to do everything in their power to keep this drug available.